New interim analysis from the pan-European PEARL Phase IV study reveals that Teva Pharmaceutical Industries’ AJOVY (fremanezumab) has led to a significant reduction in monthly migraine days for almost 60% of patients. The migraine prevention drug also showed sustained improvement in disability scores and acute medication use over 12 months. The data further show that […]
Teva Pharmaceuticals and MedinCell have bagged approval for UZEDY (risperidone) extended-release injectable suspension from the US Food and Drug Administration (FDA) for schizophrenia treatment in adults. UZEDY is a subcutaneous, long-acting formulation of risperidone that uses MedinCell’s copolymer technology SteadyTeq that regulates the fixed release of risperidone. Therapeutic blood concentrations are achieved within six to […]
NATCO Pharma said that it has launched additional strengths for the generic version of Revlimid (lenalidomide capsules), in the strengths of 2.5mg and 20mg in the US. The Indian pharma company has launched the product through its marketing partner Teva Pharmaceuticals, which is a US-based affiliate of Israeli pharma company Teva Pharmaceutical Industries. With the […]
Teva Pharmaceutical Industries said that its US affiliate Teva Pharmaceuticals has secured approval for AUSTEDO XR (deutetrabenazine) extended-release tablets from the US Food and Drug Administration (FDA) for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). AUSTEDO XR is a new daily once formulation. Expected to be launched in the US later this […]
Natco Pharma has secured the final approval from the US Food and Drug Administration (FDA) of its abbreviated new drug application (ANDA) for Lenalidomide Capsules, 5mg, 1 Omg, 15mg, and 25mg, and the tentative approval of the 2.5mg and 20mg. Lenalidomide Capsules is the generic for Bristol-Myers Squibb’s REVLIMID, which is indicated in the US […]
Teva Pharmaceutical Industries has unveiled its generic version of Elidel (pimecrolimus) Cream, 1%, providing a more affordable treatment option for individuals battling mild to moderate eczema. This significant launch addresses a critical gap for patients seeking cost-effective alternatives in eczema management, especially for those who have not responded well to traditional therapies. The prescription cream […]
German health care company Fresenius Kabi has announced the US launch of its new generic drug, Arsenic Trioxide Injection. This product, a generic version of Teva Pharmaceutical Industries’ leukemia treatment Trisenox, is set to offer a more affordable option for patients battling acute promyelocytic leukemia (APL). Arsenic Trioxide Injection for Acute Promyelocytic Leukemia Arsenic Trioxide […]
Teva Pharmaceutical Industries has achieved a significant regulatory milestone with the U.S. Food and Drug Administration (FDA) approving Ajovy (fremanezumab-vfrm) injection for migraine prevention in adults. The approval marks a pivotal advancement in migraine care, positioning Ajovy as the first anti-calcitonin gene-related peptide (CGRP) treatment approved in the United States with both quarterly (675 mg) […]
Teva Pharmaceutical Industries and Regeneron Pharmaceuticals have announced successful outcomes from their phase 3 study of fasinumab, a nerve growth factor (NGF) antibody, in patients suffering from chronic pain due to osteoarthritis (OA) of the knee or hip. The study met both co-primary endpoints and all key secondary endpoints, signaling a potential new treatment option […]
Teva Pharmaceutical Industries, the Israel-based generic drug manufacturer, has unveiled a drastic two-year restructuring plan aimed at rejuvenating its business and enhancing financial performance. The plan includes the elimination of 14,000 positions, representing over a quarter of its global workforce. This move is part of a broader strategy to reduce the company’s overall cost base […]